Total Payments
$1.3M
2024 Payments
$170,466
Companies
53
Transactions
1,236
Medicare Patients
1,369
Medicare Billing
$118,277
Payment Breakdown by Category
Other$861,601 (67.7%)
Consulting$304,235 (23.9%)
Travel$72,713 (5.7%)
Food & Beverage$21,876 (1.7%)
Research$8,400 (0.7%)
Education$3,670 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $652,476 | 285 | 51.3% |
| Consulting Fee | $304,235 | 129 | 23.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $135,500 | 38 | 10.6% |
| Travel and Lodging | $72,713 | 370 | 5.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $38,525 | 16 | 3.0% |
| Honoraria | $35,100 | 21 | 2.8% |
| Food and Beverage | $21,876 | 368 | 1.7% |
| Unspecified | $8,400 | 1 | 0.7% |
| Education | $3,670 | 8 | 0.3% |
Payments by Type
General
$1.3M
1,235 transactions
Research
$8,400
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $213,085 | 237 | $0 (2020) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $144,671 | 143 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $93,784 | 92 | $0 (2017) |
| Phathom Pharmaceuticals, Inc. | $79,631 | 95 | $0 (2024) |
| Ardelyx, Inc. | $75,549 | 56 | $0 (2024) |
| QOL Medical, LLC | $73,015 | 93 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $56,941 | 36 | $0 (2021) |
| Synergy Pharmaceuticals Inc | $55,634 | 59 | $0 (2018) |
| Alnylam Pharmaceuticals Inc. | $54,088 | 54 | $0 (2024) |
| Shire North American Group Inc | $54,055 | 34 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $170,466 | 195 | Phathom Pharmaceuticals, Inc. ($74,631) |
| 2023 | $153,775 | 134 | Ardelyx, Inc. ($30,019) |
| 2022 | $117,461 | 107 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($24,207) |
| 2021 | $130,529 | 99 | Medtronic, Inc. ($45,080) |
| 2020 | $104,708 | 79 | Takeda Pharmaceuticals U.S.A., Inc. ($38,064) |
| 2019 | $99,966 | 109 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($47,361) |
| 2018 | $153,727 | 158 | Allergan Inc. ($59,298) |
| 2017 | $341,862 | 355 | Allergan Inc. ($142,990) |
All Payment Transactions
1,236 individual payment records from CMS Open Payments — Page 1 of 50
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Honoraria | Cash or cash equivalent | $6,250.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/16/2024 | ABBVIE INC. | LINZESS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,900.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Education | In-kind items and services | $99.00 | General |
| Category: Immunology | ||||||
| 12/11/2024 | AstraZeneca AB | — | Consulting Fee | Cash or cash equivalent | $537.00 | General |
| 12/11/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $403.10 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $76.99 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $35.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | Cash or cash equivalent | $21.55 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/09/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,375.00 | General |
| Category: Gastroenterology | ||||||
| 12/09/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/05/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Travel and Lodging | Cash or cash equivalent | $338.95 | General |
| Category: Gastroenterology | ||||||
| 12/04/2024 | QOL Medical, LLC | SUCRAID (Drug) | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| Category: THERAPY FOR CSID | ||||||
| 12/04/2024 | QOL Medical, LLC | SUCRAID (Drug) | Travel and Lodging | Cash or cash equivalent | $60.50 | General |
| Category: THERAPY FOR CSID | ||||||
| 12/04/2024 | QOL Medical, LLC | SUCRAID (Drug) | Travel and Lodging | Cash or cash equivalent | $7.00 | General |
| Category: THERAPY FOR CSID | ||||||
| 12/04/2024 | QOL Medical, LLC | SUCRAID (Drug) | Travel and Lodging | Cash or cash equivalent | $2.70 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/26/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $240.35 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/26/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $155.96 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/22/2024 | Phathom Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $215.46 | General |
| 11/22/2024 | Phathom Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $71.58 | General |
| 11/22/2024 | Phathom Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $59.17 | General |
| 11/22/2024 | Phathom Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 11/22/2024 | Phathom Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 11/21/2024 | Phathom Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $570.96 | General |
| 11/20/2024 | QOL Medical, LLC | SUCRAID (Drug) | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| Category: THERAPY FOR CSID | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOPAZ | COVIDIEN LP | $8,400 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 323 | 358 | $162,070 | $28,588 |
| 2022 | 11 | 319 | 363 | $190,442 | $29,348 |
| 2021 | 16 | 425 | 457 | $230,971 | $36,550 |
| 2020 | 15 | 302 | 320 | $141,047 | $23,791 |
Total Patients
1,369
Total Services
1,498
Medicare Billing
$118,277
Procedure Codes
65
All Medicare Procedures & Services
65 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 38 | 39 | $20,241 | $5,552 | 27.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 40 | 49 | $22,344 | $5,329 | 23.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 38 | 53 | $16,801 | $3,769 | 22.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 25 | $7,075 | $2,104 | 29.7% |
| 91010 | Study of esophagus to assess movement | Facility | 2023 | 39 | 40 | $16,000 | $1,965 | 12.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2023 | 14 | 14 | $18,452 | $1,669 | 9.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $5,685 | $1,612 | 28.4% |
| 91010 | Study of esophagus to assess movement | Office | 2023 | 32 | 32 | $12,800 | $1,602 | 12.5% |
| 91122 | Study of rectum sensitivity and function | Office | 2023 | 15 | 15 | $5,220 | $1,072 | 20.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 13 | 13 | $12,714 | $1,042 | 8.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2023 | 12 | 12 | $11,736 | $879.54 | 7.5% |
| 91035 | Monitoring and recording of esophageal function through a capsule attached to the esophagus wall | Office | 2023 | 12 | 12 | $3,948 | $795.84 | 20.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 12 | $2,676 | $547.14 | 20.4% |
| 91038 | Prolonged monitoring and recording of esophageal function through nasal tube with electrode | Office | 2023 | 12 | 12 | $2,748 | $537.60 | 19.6% |
| 91065 | Measurement of hydrogen in breath to test for stomach and bowel symptoms | Office | 2023 | 14 | 15 | $3,630 | $112.42 | 3.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 32 | 45 | $20,520 | $4,824 | 23.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 37 | 57 | $16,131 | $4,584 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 46 | 57 | $18,069 | $4,120 | 22.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 12 | 12 | $18,672 | $2,351 | 12.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 16 | 16 | $8,304 | $2,289 | 27.6% |
| 91010 | Study of esophagus to assess movement | Office | 2022 | 40 | 40 | $16,000 | $1,961 | 12.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2022 | 12 | 12 | $15,816 | $1,511 | 9.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $5,685 | $1,373 | 24.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 15 | 15 | $19,770 | $1,298 | 6.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 17 | 17 | $16,626 | $1,221 | 7.3% |
About Dr. Brooks Cash, MD
Dr. Brooks Cash, MD is a Gastroenterology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1114920626.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brooks Cash, MD has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $170,466 received in 2024. These payments were reported across 1,236 transactions from 53 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($652,476).
As a Medicare-enrolled provider, Cash has provided services to 1,369 Medicare beneficiaries, totaling 1,498 services with total Medicare billing of $118,277. Data is available for 4 years (2020–2023), covering 65 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Houston, TX
- Active Since 05/31/2005
- Last Updated 10/29/2025
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1114920626
Products in Payments
- LINZESS (Drug) $214,704
- XIFAXAN (Drug) $165,508
- VOQUEZNA (Drug) $78,462
- IBSRELA (Drug) $72,174
- DUPIXENT (Biological) $59,781
- Trulance (Drug) $55,634
- SUCRAID (Drug) $50,152
- MOTEGRITY (Drug) $49,254
- GIVLAARI (Drug) $47,044
- VIBERZI (Drug) $29,532
- ANDEXXA (Biological) $28,479
- TRULANCE (Drug) $28,440
- Sucraid (Drug) $22,864
- MOVANTIK (Drug) $20,291
- PLENVU (Drug) $20,168
- COLOGUARD (Device) $17,337
- Talicia (Drug) $17,111
- Movantik (Drug) $13,053
- RELISTOR (Drug) $10,001
- NASCOBAL (Drug) $9,187
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Houston
Dr. Bincy Abraham, Md, MD
Gastroenterology — Payments: $1.9M
Gastroenterology $1.9M
Dr. Isaac Raijman, Md, MD
Gastroenterology — Payments: $1.6M
Gastroenterology $1.6M
Dr. Mazen Noureddin, M.d, M.D
Gastroenterology — Payments: $786,099
Gastroenterology $786,099
Dr. Jason Hou, M.d, M.D
Gastroenterology — Payments: $372,514
Gastroenterology $372,514
Kalpesh Patel, Md, MD
Gastroenterology — Payments: $313,187
Gastroenterology $313,187
Dr. Nirav Thosani, Md, MD
Gastroenterology — Payments: $251,409
Gastroenterology $251,409